Atossa Therapeutics, Inc.
ATOSNasdaqCIK 1488039HealthcareFiscal year ends Dec 31
Reports and events: 298 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-0912:15 ET | 8-K | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-418560 |
| 2026-09-2912:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-406036 |
| 2026-09-1821:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-395694 |
| 2026-08-0712:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-339292 |
| 2026-08-0712:30 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-339257 |
| 2026-06-1112:00 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-266717 |
| 2026-05-0812:45 ET | 8-K | 9.01 Financial statements and exhibits | 0001193125-26-213439 |
| 2026-05-0812:30 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-213423 |
| 2026-05-0812:00 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-213373 |
| 2026-04-1612:30 ET | 8-K | 8.01 Other events | 0001193125-26-158030 |
| 2026-03-3021:30 ET | DEF 14A | Proxy statementPeriod 2026-03-30 | 0001193125-26-131807 |
| 2026-03-2521:21 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-124396 |
| 2026-03-2521:20 ET | 8-K | 9.01 Financial statements and exhibits | 0001193125-26-124393 |
| 2026-02-2021:22 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-061412 |
| 2026-02-1721:30 ET | 8-K | 3.01 Delisting notice | 0001193125-26-054797 |
| 2026-02-1113:45 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-045628 |
| 2026-01-2613:00 ET | 8-K | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-021727 |
| 2026-01-0913:15 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-008314 |
| 2026-01-0613:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-003506 |
| 2025-12-2213:30 ET | DEF 14A | Proxy statementPeriod 2025-12-19 | 0001193125-25-327630 |
| 2025-12-0413:15 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-307516 |
| 2025-11-1213:45 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-276160 |
| 2025-11-1213:40 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-276140 |
| 2025-10-1411:50 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure | 0001193125-25-238065 |
| 2025-09-2621:12 ET | 8-K | 7.01 Regulation FD disclosure | 0001193125-25-220788 |
| 2025-09-0812:36 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-113371 |
| 2025-08-2120:05 ET | 8-K | 3.01 Delisting notice | 0000950170-25-110654 |
| 2025-08-1212:45 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-106947 |
| 2025-08-1212:40 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-106944 |
| 2025-05-1312:15 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-069827 |
| 2025-05-1312:05 ET | 8-K | 2.02 Results of operations | 0000950170-25-069818 |
| 2025-05-1222:00 ET | 8-K | 5.07 Shareholder vote results | 0000950170-25-068333 |
| 2025-04-0720:05 ET | 8-K | 8.01 Other events | 0000950170-25-051575 |
| 2025-03-2620:30 ET | DEF 14A | Proxy statementPeriod 2025-03-26 | 0000950170-25-045297 |
| 2025-03-2512:10 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-044099 |
| 2025-03-2512:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-044098 |
| 2025-03-1213:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-037634 |
| 2025-02-2421:05 ET | 8-K | 3.01 Delisting notice | 0000950170-25-025596 |
| 2025-02-0414:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-012868 |
| 2024-12-1014:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-134779 |
| 2024-11-1921:35 ET | 8-K | 1.01 Entry into a material agreement | 0000950170-24-128686 |
| 2024-11-1213:35 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-124668 |
| 2024-11-1213:30 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-124655 |
| 2024-11-0411:35 ET | 8-K | 8.01 Other events | 0000950170-24-120268 |
| 2024-08-1213:05 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-095102 |
| 2024-08-1213:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-095097 |
| 2024-07-0220:20 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-24-080497 |
| 2024-05-2313:00 ET | DEF 14A | Proxy statementPeriod 2024-05-23 | 0000950170-24-063763 |
| 2024-05-1313:05 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-058244 |
| 2024-05-1313:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-058242 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:08 ET. Listed shows no prices and gives no investment advice.